<DOC>
	<DOCNO>NCT00730847</DOCNO>
	<brief_summary>This study collect clinical data ( safety reactogenicity ) GlaxoSmithKline Biologicals ' human papillomavirus ( HPV ) vaccine local target population per Bureau Food Drugs Directive Philippines .</brief_summary>
	<brief_title>Evaluate Safety Vaccine Against Cervical Cancer ( HPV-16/18 L1/AS04 ) Healthy Filipino Females Aged 10 Yrs &amp; Above</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe and/or LAR 's comply requirement protocol enrol study . A female 10 year age time first vaccination . Written inform consent obtain subject . For subject legal age consent , write informed consent must obtain parent legal guardian ( legally acceptable representative LAR ) subject inform assent must obtain subject . Free obvious health problem establish medical history historydirected physical examination enter study . Subjects childbearing potential must pregnant . Subjects must nonchildbearing potential , subject childbearing potential , must abstinent ( , must document source document vaccination visit ) must use adequate contraception 30 day prior vaccination continue 2 month completion vaccination series . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Concurrently participate another clinical study time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Pregnant breastfeeding . Planning become pregnant likely become pregnant ( determined investigator ) planning discontinue contraceptive prevention study period two month last vaccine dose . History allergic disease , suspect allergy reaction likely exacerbate component study vaccine . Hypersensitivity latex ( find syringetip cap plunger ) . Known acute chronic , clinically significant neurologic , haematological , hepatic renal functional abnormality , determine previous physical examination laboratory test . Cancer autoimmune disease treatment Previous vaccination HPV plan administration another HPV vaccine study . Acute disease time enrolment .</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>PMS</keyword>
	<keyword>Post-marketing surveillance</keyword>
	<keyword>Safety</keyword>
	<keyword>Prescribing Information</keyword>
	<keyword>Philippines</keyword>
	<keyword>HPV</keyword>
	<keyword>Human papillomavirus</keyword>
</DOC>